NEW YORK ( TheStreet) -- CHANGE IN RATINGSBoeing ( BA) upgraded at Jesup & Lamont from Hold to Buy. $63 price target. Stock is trading at an attractive risk/reward ratio. Boeing ( BA) upgraded at Barclays to Overweight from Equal Weight. Price target jumped to $65 from $57. 2009 and 2010 EPS estimates lowered to $1.20 and $4.40, respectively. Beckman Coulter ( BEC) upgraded at JP Morgan. Rating raised to Overweight from Neutral. Maintains $75 price target and 2009 EPS estimates of $3.82. Boston Scientific ( BSX) downgraded at Baird from Outperform to Neutral. $10 price target. Company is reliant on slow-growth markets. Bucyrus ( BUCY) target, estimate raised at Barclays. BUCY price target surged to $73 from $64. 2010 EPS estimate increased to $3.55 from $2.90. Maintain Overweight rating. Bucyrus ( BUCY) rated new Outperform at Morgan Stanley. $71 price target. Terex purchase was a positive and should materially add to earnings. Chesapeake Energy ( CHK) downgraded at Goldman from Buy to Neutral. Valuation call, despite the company's attractive resource upside. Con-way ( CNW) upgraded at BofA/Merrill to Buy from Neutral. Price target set at $45. YRC's market share losses makes valuation increasingly attractive for CNW. Calpine ( CPN) upgraded at Jefferies from Underperform to Hold. $11.50 price target. Company has reduced exposure to gas and trades at an attractive valuation. Dynegy ( DYN) upgraded at Jefferies from Underperform to Hold. Valuation call, based on a $1.80 price target. Brinker ( EAT) downgraded at UBS from Buy to Neutral. $16 price target. Estimates also lowered, as sales trends appear to have deteriorated.
Emdeon ( EM) upgraded at Brean Murray from Sell to Hold. Company is likely to exceed conservative earnings expectations. Edwards Lifesciences ( EW) upgraded at Baird from Neutral to Outperform. $103 price target. Sapien launch should be successful. Expedia ( EXPE) downgraded at Credit Suisse to Neutral from Outperform as risk/reward appears balanced. Price target cut by a dollar to $28. 2009 and 2010 EPS estimates set at $1.37 and $1.44, respectively. Hansen Medical ( HNSN) downgraded at JP Morgan. Rating lowered to Neutral from Overweight. Eliminates price target. Lowers 2009 EPS estimates to -$1.45 from -$1.42. Intel ( INTC) upgraded at Baird from Neutral to Outperform. $26 price target. Expect further growth in PC sales trends. Las Vegas Sands ( LVS) upgraded at UBS from Neutral to Buy. $20 price target. Expect the company to take market share in a growing Macau market. Mercadolibre ( MELI) downgraded at JP Morgan. Rating lowered to Neutral from Overweight. Maintains $51 price target and 2009 EPS estimates of $0.74. Morgan Stanley ( MS) upgraded at Credit Suisse to Outperform from Neutral. Anticipating weak 4Q but 2010 should see margins and book value growth, Credit Suisse said. Price target raised to $38 from $32. 2009 EPS sunk to -$1.08, 2010 raised to $3.20. Morgan Stanley ( MS) upgraded at UBS from Neutral to Buy. $37 price target. Investment Banking pipeline is building and management is turning around some areas that have struggled. NII Holdings ( NIHD) rated new Buy at Citigroup. $50 price target. Stock appears under-owned and the company is operating in a sweet spot.
Plains Exploration ( PXP) rated new Neutral at Goldman. $33 price target. Company needs to execute better to attract investors. Silicon Laboratories ( SLAB) downgraded at Kaufman from Buy to Hold. $50 price target. Most recent checks suggest work down of handset inventories in Korea. UnitedHealth ( UNH) upgraded at Citigroup from Hold to Buy. Company should benefit from sector rotation. $39 price target. Ultra Petroleum ( UPL) upgraded at Goldman from Neutral to Buy. Stock also added to the Conviction List, as growth and returns should be strong outside of the price of natural gas. UPS ( UPS) upgraded at Baird from Neutral to Outperform. $70 price target. See multiple areas for operating leverage, as the environment improves. Wellcare ( WCG) downgraded at Oppenheimer from Outperform to Perform. $36 price target. Valuation call, as the company likely has limited upside earnings potential. Wynn Resorts ( WYNN) upgraded at UBS from Neutral to Buy. $76 price target. Valuation call, as the Macau gaming outlook remains steady.
STOCK COMMENTS / EPS CHANGESAtmel ( ATML) added to Focus List at Kaufman. $6 price target. Channel checks show strong demand across key segments. Buy rating. Bristol-Myers ( BMY) target upped at Goldman. Shares of BMY now seen reaching $26. MJN split will boost the company's earnings. Neutral rating. Citigroup ( C) estimate lower at Credit Suisse. C 2009 EPS to -$0.60 from -$0.05, 2010 set at $0.12. Maintain Neutral rating and $4.50 price target. CME Group ( CME) estimates cut at Barclays. Barclays lowered CME 2009 and 2010 EPS estimates to $13.25 and $15.68, respectively. Maintain Equal Weight rating and $315 price target.
Express Scripts ( ESRX) target boosted at Citigroup Shares of ESRX now seen reaching $112, according to Citigroup. Industry has favorable tailwinds. Buy rating. Google ( GOOG) estimates, target raised at FBR. Shares of GOOG now seen reaching $810. Estimates also boosted, to reflect channel checks and the latest traffic data. Outperform rating. Goldman Sachs ( GS) estimate cut at Credit Suisse. GS 2009 EPS estimate to $18.08 from $19.30, 2010 set at $17.75. Maintain Outperform rating and $225 price target. Intercontinental Exchange ( ICE) target, estimates cut at Barclays. ICE price target lowered by $3 to $116. 2009 and 2010 EPS estimates reduced to $4.45 and $5.26, respectively. Maintain Overweight rating. Joy Global ( JOYG) target, estimates raised at Barclays to $67 from $64 on faster recovery. 2010 EPS estimate improved to $3.05, 2011 introduced at $3.95. Reiterate Overweight rating. Mariner Energy ( ME) price target lowered at Credit Suisse by a dollar to $15. 2009 and 2010 EPS estimates set at $0.70 and $0.03, respectively. Outperform rating. Medco Health ( MHS) target increased at Citigroup. MHS target was boosted to $77. Prescription trends remain favorable. Buy rating. Merck ( MRK) numbers boosted at Citigroup. MRK estimates were increased through 2013. Company should see significant synergies from the SGP deal. Buy rating and new $45 price target. NYSE Euronext ( NYX) estimates lower at Barclays. Barclays reduced NYX 2009 and 2010 EPS estimates to $1.94 and $2.28, respectively. Reiterate Overweight rating and $35 price target. Sprint Nextel ( S) estimates lowered at Goldman through 2011. Company to see higher losses following the recent Clearwire financing. Neutral rating.
Skyworks ( SWKS) estimates, target boosted at Oppenheimer. Shares now seen reaching $17. Estimates also raised, as channel checks show the company has strong order momentum. Outperform rating. AT&T ( T) estimates boosted at Goldman through 2011. Centennial acquisition should add to earnings. Buy rating. Veeco Instruments ( VECO) price target raised at BofA/Merrill to $40 from $33 as LED cycle remains robust. Reiterate Buy rating.